08 August 2017

By Dr Wendy Winnall - PCFA Research Team

Early androgen deprivation therapy: a trade-off between quality and length of life

Androgen deprivation therapy (ADT) is a common treatment for advanced prostate cancer and for men whose cancer has spread after initial treatment for localised disease. ADT has many debilitating side effects that result from suppressing the effects of testosterone. Often men having ADT have a rising PSA, but few symptoms arising from the actual cancer. There is evidence that giving ADT early to these men can improve survival rates. But this comes at a cost; men with few or no symptoms from their prostate cancer suffer significant side effects from ADT to help them live longer. A new Australian study has specifically compared the quality of life for men undergoing early or delayed ADT.

To read the full article just log into the PCFA Online Community.

If you're not already a member, it is free and easy to join.


Join Online Community Button